关于：新型冠状病毒2019（SARS-CoV-2）特异性抗体的概况：首次报告。 - Suppr

Suppr

超能文献

Re: Profile of specific antibodies to SARS-CoV-2: The first report.

作者信息

Zeng Zhikun, Chen Liangjun, Pan Yunbao, Deng Qiaoling, Ye Guangming, Li Yirong, Wang Xinghuan

机构信息

Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, Hubei, China.

出版信息

J Infect. 2020 Jul;81(1):e80-e81. doi: 10.1016/j.jinf.2020.03.052. Epub 2020 Apr 10.

DOI:10.1016/j.jinf.2020.03.052

PMID:32283140

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7194903/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd04/7194903/dd9da3d62982/gr1_lrg.jpg

相似文献

Re: Profile of specific antibodies to SARS-CoV-2: The first report.

J Infect. 2020 Jul;81(1):e80-e81. doi: 10.1016/j.jinf.2020.03.052. Epub 2020 Apr 10.

Profile of specific antibodies to SARS-CoV-2: The first report.

J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.012. Epub 2020 Mar 21.

Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19).

Travel Med Infect Dis. 2020 May-Jun;35:101608. doi: 10.1016/j.tmaid.2020.101608. Epub 2020 Feb 27.

Re: Testing recommendation for COVID-19 (SARS-CoV-2) in patients planned for surgery - continuing the service and 'suppressing' the pandemic.

Br J Oral Maxillofac Surg. 2020 Jul;58(6):733. doi: 10.1016/j.bjoms.2020.05.012. Epub 2020 May 16.

Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.

N Engl J Med. 2020 Oct 22;383(17):1694-1695. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23.

The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times.

Respirology. 2020 Jul;25(7):680-682. doi: 10.1111/resp.13852. Epub 2020 May 20.

Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. Reply.

N Engl J Med. 2020 Oct 22;383(17):1697-1698. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23.

Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.

N Engl J Med. 2020 Oct 22;383(17):1695-1696. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23.

Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.

N Engl J Med. 2020 Oct 22;383(17):1695. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23.

From SARS-CoV to SARS-CoV-2: The response and challenge of forensic infectious disease autopsy.

Fa Yi Xue Za Zhi. 2020 Feb;36(1):1-3. doi: 10.12116/j.issn.1004-5619.2020.01.001. Epub 2020 Feb 25.

引用本文的文献

The correlation between humoral immune responses and severity of clinical symptoms in COVID-19 patients.

Epidemiol Infect. 2023 Sep 11;151:e158. doi: 10.1017/S0950268823001437.

Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19.

Microbiol Spectr. 2023 Aug 17;11(4):e0469022. doi: 10.1128/spectrum.04690-22. Epub 2023 Jun 6.

Antibody tests for identification of current and past infection with SARS-CoV-2.

Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.

Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.

BMC Infect Dis. 2022 Jan 4;22(1):10. doi: 10.1186/s12879-021-07010-w.

Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19.

Signal Transduct Target Ther. 2021 Aug 25;6(1):316. doi: 10.1038/s41392-021-00731-z.

High Performance of SARS-Cov-2N Protein Antigen Chemiluminescence Immunoassay as Frontline Testing for Acute Phase COVID-19 Diagnosis: A Retrospective Cohort Study.

Front Med (Lausanne). 2021 Jul 14;8:676560. doi: 10.3389/fmed.2021.676560. eCollection 2021.

Mass SARS-CoV-2 molecular and serological screening of medical staff and patients in Hangzhou, China: no evidence of RNA detection, low seroprevalence, and limited exposure risk in the hospital setting.

Ann Transl Med. 2021 Apr;9(7):552. doi: 10.21037/atm-20-7163.

Review of the Microbiological Diagnostic Approaches of COVID-19.

Front Public Health. 2021 Apr 27;9:592500. doi: 10.3389/fpubh.2021.592500. eCollection 2021.

SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients.

Front Immunol. 2021 Mar 23;12:629185. doi: 10.3389/fimmu.2021.629185. eCollection 2021.

Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand.

Clin Transl Immunology. 2021 Mar 14;10(3):e1261. doi: 10.1002/cti2.1261. eCollection 2021.

本文引用的文献

Profile of specific antibodies to SARS-CoV-2: The first report.

J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.012. Epub 2020 Mar 21.

Positive RT-PCR Test Results in Patients Recovered From COVID-19.

JAMA. 2020 Apr 21;323(15):1502-1503. doi: 10.1001/jama.2020.2783.

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak.

Emerg Microbes Infect. 2020 Feb 5;9(1):313-319. doi: 10.1080/22221751.2020.1725399. eCollection 2020.

The Immunobiology of SARS*.

Annu Rev Immunol. 2007;25:443-72. doi: 10.1146/annurev.immunol.25.022106.141706.

Neutralizing antibody response and SARS severity.

Emerg Infect Dis. 2005 Nov;11(11):1730-7. doi: 10.3201/eid1111.040659.

Profile of specific antibodies to the SARS-associated coronavirus.

N Engl J Med. 2003 Jul 31;349(5):508-9. doi: 10.1056/NEJM200307313490520.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Re: Profile of specific antibodies to SARS-CoV-2: The first report.

J Infect. 2020 Jul;81(1):e80-e81. doi: 10.1016/j.jinf.2020.03.052. Epub 2020 Apr 10.

Profile of specific antibodies to SARS-CoV-2: The first report.

J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.012. Epub 2020 Mar 21.

Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19).

Travel Med Infect Dis. 2020 May-Jun;35:101608. doi: 10.1016/j.tmaid.2020.101608. Epub 2020 Feb 27.

Re: Testing recommendation for COVID-19 (SARS-CoV-2) in patients planned for surgery - continuing the service and 'suppressing' the pandemic.

Br J Oral Maxillofac Surg. 2020 Jul;58(6):733. doi: 10.1016/j.bjoms.2020.05.012. Epub 2020 May 16.

Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.

N Engl J Med. 2020 Oct 22;383(17):1694-1695. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23.

The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times.

Respirology. 2020 Jul;25(7):680-682. doi: 10.1111/resp.13852. Epub 2020 May 20.

Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. Reply.

N Engl J Med. 2020 Oct 22;383(17):1697-1698. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23.

Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.

N Engl J Med. 2020 Oct 22;383(17):1695-1696. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23.

Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.

N Engl J Med. 2020 Oct 22;383(17):1695. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23.

From SARS-CoV to SARS-CoV-2: The response and challenge of forensic infectious disease autopsy.

Fa Yi Xue Za Zhi. 2020 Feb;36(1):1-3. doi: 10.12116/j.issn.1004-5619.2020.01.001. Epub 2020 Feb 25.

引用本文的文献

The correlation between humoral immune responses and severity of clinical symptoms in COVID-19 patients.

Epidemiol Infect. 2023 Sep 11;151:e158. doi: 10.1017/S0950268823001437.

Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19.

Microbiol Spectr. 2023 Aug 17;11(4):e0469022. doi: 10.1128/spectrum.04690-22. Epub 2023 Jun 6.

Antibody tests for identification of current and past infection with SARS-CoV-2.

Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.

Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.

BMC Infect Dis. 2022 Jan 4;22(1):10. doi: 10.1186/s12879-021-07010-w.

Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19.

Signal Transduct Target Ther. 2021 Aug 25;6(1):316. doi: 10.1038/s41392-021-00731-z.

High Performance of SARS-Cov-2N Protein Antigen Chemiluminescence Immunoassay as Frontline Testing for Acute Phase COVID-19 Diagnosis: A Retrospective Cohort Study.

Front Med (Lausanne). 2021 Jul 14;8:676560. doi: 10.3389/fmed.2021.676560. eCollection 2021.

Ann Transl Med. 2021 Apr;9(7):552. doi: 10.21037/atm-20-7163.

Review of the Microbiological Diagnostic Approaches of COVID-19.

Front Public Health. 2021 Apr 27;9:592500. doi: 10.3389/fpubh.2021.592500. eCollection 2021.

SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients.

Front Immunol. 2021 Mar 23;12:629185. doi: 10.3389/fimmu.2021.629185. eCollection 2021.

Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand.

Clin Transl Immunology. 2021 Mar 14;10(3):e1261. doi: 10.1002/cti2.1261. eCollection 2021.

本文引用的文献

Profile of specific antibodies to SARS-CoV-2: The first report.

J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.012. Epub 2020 Mar 21.

Positive RT-PCR Test Results in Patients Recovered From COVID-19.

JAMA. 2020 Apr 21;323(15):1502-1503. doi: 10.1001/jama.2020.2783.

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak.

Emerg Microbes Infect. 2020 Feb 5;9(1):313-319. doi: 10.1080/22221751.2020.1725399. eCollection 2020.

The Immunobiology of SARS*.

Annu Rev Immunol. 2007;25:443-72. doi: 10.1146/annurev.immunol.25.022106.141706.

Neutralizing antibody response and SARS severity.

Emerg Infect Dis. 2005 Nov;11(11):1730-7. doi: 10.3201/eid1111.040659.

Profile of specific antibodies to the SARS-associated coronavirus.

N Engl J Med. 2003 Jul 31;349(5):508-9. doi: 10.1056/NEJM200307313490520.